Showing results (411-420 of 432) with videos related to

Sort By:
Pageof 44
Diabetologia|August 22, 2013
A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunctionJosé María Moreno-Navarrete, Xavier Escoté, Francisco Ortega, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|November 22, 2014
Executive summary of the consensus document on the management of renal disease in HIV-infected patientsJosé Luis Górriz, Félix Gutiérrez, Joan Carles Trullas, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 12, 2014
[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients], , , et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|December 4, 2014
Consensus document on the management of renal disease in HIV-infected patients, , , et al.
European Journal of Public Health|December 14, 2011
Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08)Anabel Romero, Victoria González, Anna Esteve, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 6, 2011
Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005Anabel Romero, Omar Sued, Teresa Puig, et al.
HIV Medicine|January 17, 2022
Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019Chiara Fanciulli, Juan Berenguer, Carmen Busca, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|May 30, 2015
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015), Juan Berenguer, Rosa Polo, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Nature Communications|March 4, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trialLucia Bailón, José Moltó, Adrian Curran, et al.
Pageof 44